Stockscreener 앱 받기
225.71
3.33%
7.28
Biogen Inc 주식(BIIB)의 최신 뉴스
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
Form 4 Boeing Co For: 26 September - Investing.com India
Boeing Company (BA) Stock News & Articles - 247wallst.com
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Biogen Inc. - Via Ritzau
Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar
Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com
Eisai, Biogen Win China Approval for Leqembi Self-Injection - International Business Times
Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor
Biogen (BIIB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BIIB - MarketBeat
Biogen Inc. (BIIB) Key Financial Ratios – Valuation, Profitability & More - Value Research
Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Biogen
0.67%
3.31%
자본화:
|
볼륨(24시간):